Hypantin | CAS#6202-26-2

MedKoo Cat#: 534639 | Name: Hypantin

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Hypantin is a bioactive chemical.

Chemical Structure

Hypantin

CAS#6202-26-2

Theoretical Analysis

MedKoo Cat#: 534639

Name: Hypantin

CAS#: 6202-26-2

Chemical Formula: C25H26O2

Exact Mass: 358.1933

Molecular Weight: 358.48

Elemental Analysis: C, 83.76; H, 7.31; O, 8.93

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Hypantin; Monozol; Pituitrope; BRN 3162521; BRN-3162521; BRN3162521

IUPAC/Chemical Name

4'-(Benzyloxy)-alpha,alpha'-diethyl-4-stilbenol

InChi Key

FVLDPSZNPFWQQP-OCOZRVBESA-N

InChi Code

InChI=1S/C25H26O2/c1-3-24(20-10-14-22(26)15-11-20)25(4-2)21-12-16-23(17-13-21)27-18-19-8-6-5-7-9-19/h5-17,26H,3-4,18H2,1-2H3/b25-24+

SMILES Code

OC1=CC=C(C=C1)/C(CC)=C(CC)/C2=CC=C(OCC3=CC=CC=C3)C=C2

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 358.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Waller TA, Pantin SAL, Yenior AL, Pujalte GGA. Urinary Tract Infection Antibiotic Resistance in the United States. Prim Care. 2018 Sep;45(3):455-466. doi: 10.1016/j.pop.2018.05.005. Epub 2018 Jul 9. PMID: 30115334. 2: Molina JM, Capitant C, Spire B, Pialoux G, Cotte L, Charreau I, Tremblay C, Le Gall JM, Cua E, Pasquet A, Raffi F, Pintado C, Chidiac C, Chas J, Charbonneau P, Delaugerre C, Suzan-Monti M, Loze B, Fonsart J, Peytavin G, Cheret A, Timsit J, Girard G, Lorente N, Préau M, Rooney JF, Wainberg MA, Thompson D, Rozenbaum W, Doré V, Marchand L, Simon MC, Etien N, Aboulker JP, Meyer L, Delfraissy JF; ANRS IPERGAY Study Group. On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med. 2015 Dec 3;373(23):2237-46. doi: 10.1056/NEJMoa1506273. Epub 2015 Dec 1. PMID: 26624850. 3: Terlecki-Zaniewicz L, Pils V, Bobbili MR, Lämmermann I, Perrotta I, Grillenberger T, Schwestka J, Weiß K, Pum D, Arcalis E, Schwingenschuh S, Birngruber T, Brandstetter M, Heuser T, Schosserer M, Morizot F, Mildner M, Stöger E, Tschachler E, Weinmüllner R, Gruber F, Grillari J. Extracellular Vesicles in Human Skin: Cross-Talk from Senescent Fibroblasts to Keratinocytes by miRNAs. J Invest Dermatol. 2019 Dec;139(12):2425-2436.e5. doi: 10.1016/j.jid.2019.05.015. Epub 2019 Jun 18. PMID: 31220456. 4: Molina JM, Charreau I, Chidiac C, Pialoux G, Cua E, Delaugerre C, Capitant C, Rojas-Castro D, Fonsart J, Bercot B, Bébéar C, Cotte L, Robineau O, Raffi F, Charbonneau P, Aslan A, Chas J, Niedbalski L, Spire B, Sagaon-Teyssier L, Carette D, Mestre SL, Doré V, Meyer L; ANRS IPERGAY Study Group. Post-exposure prophylaxis with doxycycline to prevent sexually transmitted infections in men who have sex with men: an open-label randomised substudy of the ANRS IPERGAY trial. Lancet Infect Dis. 2018 Mar;18(3):308-317. doi: 10.1016/S1473-3099(17)30725-9. Epub 2017 Dec 8. PMID: 29229440. 5: Fox S, Southam P, Pantin F, Kennaway R, Robinson S, Castorina G, Sánchez- Corrales YE, Sablowski R, Chan J, Grieneisen V, Marée AFM, Bangham JA, Coen E. Spatiotemporal coordination of cell division and growth during organ morphogenesis. PLoS Biol. 2018 Nov 1;16(11):e2005952. doi: 10.1371/journal.pbio.2005952. PMID: 30383040; PMCID: PMC6211367. 6: Durand-Zaleski I, Mutuon P, Charreau I, Tremblay C, Rojas D, Pialoux G, Chidiac C, Capitant C, Spire B, Cotte L, Chas J, Meyer L, Molina JM; ANRS IPERGAY Study Group. Costs and benefits of on-demand HIV preexposure prophylaxis in MSM. AIDS. 2018 Jan 2;32(1):95-102. doi: 10.1097/QAD.0000000000001658. PMID: 29210777. 7: Rojas Castro D, Delabre RM, Molina JM. Give PrEP a chance: moving on from the "risk compensation" concept. J Int AIDS Soc. 2019 Aug;22 Suppl 6(Suppl Suppl 6):e25351. doi: 10.1002/jia2.25351. PMID: 31468693; PMCID: PMC6715948. 8: Howe GW, Pantin H, Perrino T. Programs for Preventing Depression in Adolescence: Who Benefits and Who Does Not? An Introduction to the Supplemental Issue. Prev Sci. 2018 Feb;19(Suppl 1):1-5. doi: 10.1007/s11121-018-0870-0. PMID: 29368296. 9: Lämmermann I, Terlecki-Zaniewicz L, Weinmüllner R, Schosserer M, Dellago H, de Matos Branco AD, Autheried D, Sevcnikar B, Kleissl L, Berlin I, Morizot F, Lejeune F, Fuzzati N, Forestier S, Toribio A, Tromeur A, Weinberg L, Higareda Almaraz JC, Scheideler M, Rietveld M, El Ghalbzouri A, Tschachler E, Gruber F, Grillari J. Blocking negative effects of senescence in human skin fibroblasts with a plant extract. NPJ Aging Mech Dis. 2018 Apr 11;4:4. doi: 10.1038/s41514-018-0023-5. PMID: 29675264; PMCID: PMC5895844. 10: Kovacsovics TJ, Mims A, Salama ME, Pantin J, Rao N, Kosak KM, Ahorukomeye P, Glenn MJ, Deininger MWN, Boucher KM, Bavisotto LM, Gutierrez-Sanchez G, Kennedy TP, Marcus SG, Shami PJ. Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia. Blood Adv. 2018 Feb 27;2(4):381-389. doi: 10.1182/bloodadvances.2017013391. PMID: 29467192; PMCID: PMC5858478.